Acute Stroke Imaging Research Roadmap II.
Acute Stroke Imaging Research Roadmap II.
复制标题
急性中风成像研究路线图II。
DOI：
10.1161/strokeaha.113.002015
复制
发表时间：
2013-09
期刊：
影响因子：
8.3
通讯作者：
Stroke Imaging Research (STIR) and Virtual International Stroke Trials Archive (VISTA)-Imaging Investigators
中科院分区：
文献类型：
--
作者：
Wintermark M;Albers GW;Broderick JP;Demchuk AM;Fiebach JB;Fiehler J;Grotta JC;Houser G;Jovin TG;Lees KR;Lev MH;Liebeskind DS;Luby M;Muir KW;Parsons MW;von Kummer R;Wardlaw JM;Wu O;Yoo AJ;Alexandrov AV;Alger JR;Aviv RI;Bammer R;Baron JC;Calamante F;Campbell BC;Carpenter TC;Christensen S;Copen WA;Derdeyn CP;Haley EC Jr;Khatri P;Kudo K;Lansberg MG;Latour LL;Lee TY;Leigh R;Lin W;Lyden P;Mair G;Menon BK;Michel P;Mikulik R;Nogueira RG;Ostergaard L;Pedraza S;Riedel CH;Rowley HA;Sanelli PC;Sasaki M;Saver JL;Schaefer PW;Schellinger PD;Tsivgoulis G;Wechsler LR;White PM;Zaharchuk G;Zaidat OO;Davis SM;Donnan GA;Furlan AJ;Hacke W;Kang DW;Kidwell C;Thijs VN;Thomalla G;Warach SJ;Stroke Imaging Research (STIR) and Virtual International Stroke Trials Archive (VISTA)-Imaging Investigators
美国神经放射学会和美国神经放射学会基金会赞助了一系列工作组会议，为期12个月，最后一次会议于2013年3月9日至10日在华盛顿举行的卒中治疗学会行业圆桌会议（STAIR）期间举行。该过程汇集了血管神经学家、神经放射学家、神经影像研究科学家、美国国家神经疾病和中风研究所成员、行业代表以及美国食品和药物管理局成员，讨论中风成像研究优先事项，特别是鉴于最近测试半影成像选择概念的急性中风临床试验的负面结果。这一过程的目标是提出未来5年的研究路线图。STIR建议包括：（1）使用标准术语，与美国国家神经疾病和卒中研究所通用数据元素保持一致;（2）急性缺血性卒中试验中血运重建的标准化成像评估，包括改良的脑缺血治疗（mTICI）评分;（3）评估缺血性核心和半暗带成像方法是否符合急性缺血性卒中试验中可接受的选择工具的要求的标准化过程;（4）临床和成像数据库的特征，以促进建议3中所述的开发和测试过程;（5）临床试验的最佳研究设计，以评估先进的成像技术是否在选择急性缺血性中风患者进行血运重建治疗时增加价值;以及（6）中风神经成像网络的结构，以实施和协调上述建议。所有这些建议都与研究有关，而不是临床护理。
Society of Neuroradiology, and the Foundation of the American Society of Neuroradiology sponsored a series of working group meetings> 12 months, with the final meeting occurring during the Stroke Treatment Academy Industry Roundtable (STAIR) on March 9 to 10, 2013, in Washington, DC. This process brought together vascular neurologists, neuroradiologists, neuroimaging research scientists, members of the National Institute of Neurological Disorders and Stroke, industry representatives, and members of the US Food and Drug Administration to discuss stroke imaging research priorities, especially in the light of the recent negative results of acute stroke clinical trials that tested the concept of penumbral imaging selection. The goal of this process was to propose a research roadmap for the next 5 years. STIR recommendations include (1) the use of standard terminology, aligned with the National Institute of Neurological Disorders and Stroke Common Data Elements;(2) a standardized imaging assessment of revascularization in acute ischemic stroke trials, including a modified Treatment In Cerebral Ischemia (mTICI) score;(3) a standardized process to assess whether ischemic core and penumbral imaging methods meet the requirements to be considered as an acceptable selection tool in acute ischemic stroke trials;(4) the characteristics of a clinical and imaging data repository to facilitate the development and testing process described in recommendation no. 3;(5) the optimal study design for a clinical trial to evaluate whether advanced imaging adds value in selecting acute ischemic stroke patients for revascularization therapy; and (6) the structure of a stroke neuroimaging network to implement and coordinate the recommendations listed above. All of these recommendations pertain to research, not to clinical care.